Compositions comprising secreted extracellular vesicles of cells expressing NFATC4 useful for the treatment of cancer
The present invention relates to a composition comprising secreted extracellular vesicles (SEV) of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4(NFATC4), for use in the treatment of cancer or in the treatment or prevention of metastatic cancer. It further relates to in vitromethods for determining or predicting the therapeutic efficiency of a treatment with a composition comprising SEV of cells expressing NFATC4 in a cancer patient, based on the ability of the composition comprising SEV of cells expressing NFATC4 to induce an increase in TGFβ1 expression level.
1. A method for treating cancer or for treating metastatic cancer in a patient in need thereof, comprising administering to said patient a therapeutically efficient amount of a composition comprising secreted extracellular vesicles (SEV) of cells expressing the nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (NFATC4).
2. The method according to claim 1 , wherein said SEV of cells expressing NFATC4 are purified from cancer cells with low invasive capacity.
3. The method according to claim 2 , wherein said SEV of cells expressing NFATC4 are purified from breast cancer cells with low invasive capacity.
4. The method according to claim 1 , wherein said SEV of cells expressing NFATC4 are purified from cells transfected with an expression vector comprising a nucleic acid molecule encoding NFATC4.
5. The method according to claim 4 , wherein said cells transfected by the expression vector comprising the nucleic acid molecule encoding NFATC4 are selected from:
cancer cells with low invasive capacity, and
healthy cells.
6. The method according to claim 5 , wherein said healthy cells are autologous fibroblasts or human embryonic cells.
7. The method according to claim 5 , wherein said healthy cells are HEK293T cells.
8. The method according to claim 1 , wherein said cancer is selected from solid cancers.
9. The method according to claim 8 , wherein said solid cancer is selected from breast carcinoma, pancreatic carcinoma, and glioblastoma.
10. The method according to claim 1 , wherein said composition comprising SEV of cells expressing NFATC4 is administered intravenously or intratumorally.
11. An in vitro method for determining the therapeutic efficiency of treatment with a composition comprising SEV of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (NFATC4) in a cancer patient, said method comprising:
a) providing a first biological sample from said cancer patient taken before the beginning of the treatment and a second corresponding biological sample from said cancer patient after the beginning of the treatment;
b) measuring the transforming growth factor beta 1 (TGFβ1) expression level in said first and second biological samples;
c) comparing the measured TGFβ1 expression levels; and
d) determining the efficiency of the treatment with the composition comprising SEV of cells expressing NFATC4 in said treated cancer patient from said comparison, wherein the treatment is determined efficient if the TGFβ1 expression level measured in the second biological sample is higher than the TGFβ1 expression level in the first biological sample.
12. The method according to claim 11 , wherein said biological sample is a tumor sample, a blood sample, a serum sample, or a urine sample.
13. The method according to claim 11 , wherein the expression level of TGFβ1 in the two biological samples of said cancer patient is measured at the nucleic acid level or at the protein level.
14. The method according to claim 11 , wherein said cancer is selected from solid cancers.
15. The method according to claim 14 , wherein said solid cancer is selected from breast carcinoma, pancreatic carcinoma, and glioblastoma.
16. An in vitro method for predicting the therapeutic efficiency of treatment with a composition comprising SEV of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (NFATC4) in a cancer patient, said method comprising:
a) providing a first biological sample and a second corresponding biological sample from said cancer patient taken before the beginning of the treatment;
b) incubating the second biological sample with the composition comprising SEV of cells expressing NFATC4;
c) measuring the transforming growth factor beta 1 (TGFβ1) expression level in said first and second biological samples;
d) comparing the measured TGFβ1 expression levels; and
e) predicting the efficiency of the treatment with the composition comprising SEV of cells expressing NFATC4 in said cancer patient from said comparison, wherein the treatment is predicted efficient if the TGFβ1 expression level measured in the second biological sample is higher than the TGFβ1 expression level in the first biological sample.
17. The method according to claim 16 , wherein said biological sample is a tumor sample, a blood sample, a serum sample, or a urine sample.
18. The method according to claim 16 , wherein the expression level of TGFβ1 in the two biological samples of said cancer patient is measured at the nucleic acid level or at the protein level.
19. The method according to claim 16 , wherein said cancer is selected from solid cancers.
20. The method according to claim 19 , wherein said solid cancer is selected from breast carcinoma, pancreatic carcinoma, and glioblastoma.